更新于：2024-12-14
IMU-201
更新于：2024-12-14
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
4
项与 IMU-201 相关的临床试验A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer
Study on the Differentiation Characteristics of Tumor-Specific Memory CD8 T Cells in Drainage Lymph Nodes and Their Response to PD-1 Immunotherapy Mechanism study
A single-center, single-arm, observational study of fruquinitinib combined with capecitabine and PD-1 in neoadjuvant therapy for colorectal cancer
100 项与 IMU-201 相关的临床结果
登录后查看更多信息
100 项与 IMU-201 相关的转化医学
登录后查看更多信息
100 项与 IMU-201 相关的专利（医药）
登录后查看更多信息
18
项与 IMU-201 相关的文献（医药）2024-09-13CLINICAL CANCER RESEARCH
Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON)
Article
作者: Petrović, Zoran ; Nagarkar, Rajnish ; Ryspayeva, Dinara ; Chawla, Tanuj ; Bulat, Iurie ; Nixon, Bonnie ; Andrić, Zoran ; Maglakelidze, Marina ; Wiedermann, Ursula ; Yavrom, Sharon ; Garner-Spitzer, Erika ; Tobias, Joshua ; Nikolić, Ivan ; Chong, Leslie Mi Ok ; Ede, Nicholas J. ; Zielinski, Christoph C. ; Kundi, Michael
Abstract:
Purpose::
A multicenter, randomized, open-label, phase II study (HERIZON; NCT02795988) was conducted to evaluate the clinical and immunologic efficacy of HER-Vaxx (IMU-131), a B-cell, peptide-based vaccine targeting HER2 overexpressed in 6% to 30% of gastroesophageal adenocarcinomas (GEA).
Patients and Methods::
Patients (n = 36) with GEA were treated with standard-of-care chemotherapy (n = 17) or HER-Vaxx plus chemotherapy (n = 19), using the recommended phase 2 dose for the vaccine. Overall survival (OS; primary endpoint), safety, progression-free survival (PFS), clinical response (secondary endpoints), and vaccine-induced HER2-specific antibody levels in serum and correlation with tumor response rates (exploratory endpoints) were investigated.
Results::
A 40% OS benefit [HR, 0.60; median OS, 13.9 months; 80% confidence interval (CI), 7.52–14.32] for patients treated with HER-Vaxx plus chemotherapy compared with OS of 8.31 months (80% CI, 6.01–9.59) in patients that received chemotherapy alone. A 20% PFS difference was obtained for the vaccination arm (HR, 0.80; 80% CI, 0.47, 1.38). No additional toxicity due to HER-Vaxx was observed. The vaccine-induced high levels of HER2-specific total IgG and IgG1 antibodies (P < 0.001 vs. controls) that significantly correlated with tumor reduction (IgG, P = 0.001; IgG1, P = 0.016), had a significant capacity in inhibiting phosphorylation of the intracellular HER2-signaling pathways, mediated antibody-dependent cellular cytotoxicity, and decreased immunosuppressive FOXP3+ regulatory T cells.
Conclusions::
HER-Vaxx plus standard chemotherapy exhibits an excellent safety profile and improves OS. Furthermore, vaccine-induced immune response was significantly associated with reduced tumor size compared with standard-of-care chemotherapy. The presented vaccination approach may substitute for treatment with trastuzumab, upon unavailability or toxicity, based on further evidence of equivalent treatment efficacy.
2024-08-09JOURNAL OF HEALTH POLITICS POLICY AND LAW
Political Partisanship, Confucian Collectivism, and Public Attitudes toward the Vaccination Policy in Taiwan
Article
作者: Hsieh, Yu-Chun ; Yeh, Ming-Jui
Abstract:
Context: Conventional wisdom suggests that people with a collectivist tradition tend to comply more with the government's regulatory and even coercive disease-prevention policies. Besides this socio-cultural element, political partisanship is also an important aspect relating to people's willingness to cooperate with the government. This study aims to examine the relationships between these two factors and three dimensions of vaccination policy attitudes: common responsibility to take the vaccine, the government's vaccine mandate, and indignation over anti-vaxxers.Methods: Using the data from a nationally representative cross-sectional survey conducted in 2022 in Taiwan, this study applies multiple linear OLS regression to examine the relationships between vaccination policy attitudes and Confucian collectivism and political partisanship.Findings: Confucian collectivism and political partisanship aligning with the ruling party are associated with supportive vaccination policy attitudes. For those who do not align with the ruling party, the negative attitudes toward the vaccination policy appear in different dimensions according to the party they lean to.Conclusions: Confucian collectivism is prevalent in Taiwan and is related to public attitudes toward vaccination policy. This association is independent of political partisanship. Public health authorities should consider the socio-cultural context and political atmosphere for the effectiveness of disease-prevention measures.
2023-12-12Microbiology spectrum
A follow-up study: 6-year cART-free virologic control of rhesus macaques after PD-1-based DNA vaccination against pathogenic SHIV
SF162P3CN
challenge
Article
作者: Wong, Yik Chun ; Li, Xin ; Mo, Yufei ; Zhong, Menglong ; Wang, Hui ; Zhang, Haoji ; Li, Bo ; Liu, Wan ; He, Xiaoen ; Chen, Zhiwei ; Du, Yanhua ; Yim, Lok Yan
ABSTRACT:
An effective vaccine for combination antiretroviral therapy (cART)-free virologic control of HIV-1 by enhancing antigen-specific effector-memory CD8
+
T lymphocytes could be useful in controlling the AIDS pandemic. Previously, we demonstrated that a programmed death-1 (PD-1)-based DNA vaccine, pRhPD1-p27, was effective in inducing Gag-p27-specific effector-memory CD8
+
T cells for viremia suppression in rhesus macaques infected with pathogenic SHIV
SF162P3CN
for 2 years. In this follow-up study, we report on two pRhPD1-p27-vaccinated and SHIV
SF162P3CN
-infected macaques that have remained alive to date with undetectable viremia levels and low proviral loads over 6 years in the absence of cART, achieving a state of sustained virologic control. Polyfunctional effector-memory Gag-p27-specific T cells were maintained in these macaques. Moreover, several T cell epitopes found at 6 years post-viral challenge were identical to those induced during the vaccination phase, indicating sustained vaccine-induced memory T cell responses. The viral challenge resulted in
de novo
Nef-specific T cell responses, which were also maintained. These Gag-p27- and Nef-specific T cell responses were stronger than those in some SHIV
SF162P3CN
-infected macaques that showed viremia control after experimental therapy using a tandem bispecific neutralizing antibody. Our findings indicate that the PD-1-based DNA vaccine strategy holds promise as a clinical immunotherapy for long-term HIV-1 suppression.
IMPORTANCE:
Efficient strategies for HIV-1 cART-free virologic control are critical for ending the AIDS pandemic. The essential role of effector-memory CD8
+
T cells in controlling viremia and eliminating virus-infected cells has made them a promising target for vaccine development. It has been previously reported that PD-1-based DNA vaccination was effective in inducing polyfunctional effector-memory CD8
+
T cells for AIDS virus control for 2 years in rhesus monkeys. This follow-up study extends the findings and shows that a viremia-free period of over 6 years was detected in two monkeys immunized with PD-1-based DNA vaccine against pathogenic SHIV
SF162P3CN
infection in the absence of antiretroviral therapy. Long-term vaccine-induced memory T cell responses were detected. Our results warrant the clinical trials of PD-1-based DNA vaccines for achieving HIV-1 cART-free virologic control used either alone or in combination with other biomedical interventions.
100 项与 IMU-201 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 错配修复缺陷或微卫星高度不稳定性结直肠癌 | 临床2期 | - | - | |
| 肺腺癌 | 临床1期 | 美国 | 2020-11-30 | |
| 肺腺癌 | 临床1期 | 澳大利亚 | 2020-11-30 | |
| 转移性非小细胞肺癌 | 临床1期 | 美国 | 2020-11-30 | |
| 转移性非小细胞肺癌 | 临床1期 | 澳大利亚 | 2020-11-30 | |
| 非小细胞肺癌IIIB期 | 临床1期 | 美国 | 2020-11-30 | |
| 非小细胞肺癌IIIB期 | 临床1期 | 澳大利亚 | 2020-11-30 | |
| 鳞状非小细胞肺癌 | 临床1期 | 美国 | 2020-11-30 | |
| 鳞状非小细胞肺癌 | 临床1期 | 澳大利亚 | 2020-11-30 | |
| 未分化大细胞肺癌 | 临床1期 | 美国 | 2020-11-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 43 | PD-1 inhibitor | 顧憲醖積繭淵廠衊遞醖(餘製範鹹餘築膚蓋衊鏇) = 艱鬱鹽淵膚糧鑰範顧鑰 蓋鏇淵繭鹽衊艱艱衊糧 (餘糧糧簾製衊鬱選衊範 ) 更多 | - | 2022-08-06 | |
PD-L1 inhibitor | 顧憲醖積繭淵廠衊遞醖(餘製範鹹餘築膚蓋衊鏇) = 淵鬱壓襯鏇壓範壓淵淵 蓋鏇淵繭鹽衊艱艱衊糧 (餘糧糧簾製衊鬱選衊範 ) 更多 | ||||||
临床1期 | 4 | 選醖製齋醖獵齋餘窪遞(構願築顧餘淵憲觸鬱願) = no observed 鑰淵艱餘願衊醖鹹衊窪 (獵憲鑰製衊窪簾鏇醖膚 ) | 积极 | 2022-06-02 | |||
N/A | 29 | Chemotherapy | 淵窪齋餘鹽繭淵獵遞鑰(襯鏇觸願糧積醖築鬱餘) = 鹹選壓獵製醖遞築衊鹹 鹹願衊簾糧構夢築襯鹹 (蓋構壓鹽顧鏇夢鬱襯窪 ) | - | 2015-05-20 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用